Shopping Cart

Your shopping cart is currently empty

Acrizanib

Name: Acrizanib
Brand: TargetMol
SKU: T5373
Price: 113 USD
Availability: InStock
Rating: 5 (10 reviews)

😃Good

Catalog No. T5373Cas No. 1229453-99-9

Alias LHA510

Acrizanib (LHA510) is a VEGFR-2 inhibitor with an IC50 of 17.4 nM for BaF3-VEGFR-2.

Acrizanib

😃Good

Purity: 99.64%

Catalog No. T5373Alias LHA510Cas No. 1229453-99-9

Acrizanib (LHA510) is a VEGFR-2 inhibitor with an IC50 of 17.4 nM for BaF3-VEGFR-2.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$113	In Stock	In Stock
5 mg	$289	In Stock	In Stock
10 mg	$446	In Stock	In Stock
25 mg	$762	In Stock	In Stock
50 mg	$1,060	In Stock	In Stock
100 mg	$1,380	-	In Stock
1 mL x 10 mM (in DMSO)	$318	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.64%

Appearance:Solid

Color:Yellow

Resource Download

COA LCMS HNMR

Product Introduction

Bioactivity

Description	Acrizanib (LHA510) is a VEGFR-2 inhibitor with an IC50 of 17.4 nM for BaF3-VEGFR-2.
Targets&IC50	VEGFR2:17.4 nM
In vitro	Acrizanib is a VEGFR-2 inhibitor with an IC50 of 17.4 nM for BaF3-KDR, and exhibits ≤10% remaining kinase activity against only 13 wild type kinases: CSF1R, Kit, PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, Fms (soluble VEGFR1), DDR1, DDR2, TIE1, and ABL1 (nonphosphorylated) [1].
In vivo	Rat ocular pharmacokinetic (PK) studies indicate that Acrizanib (compound 35) exhibits a notably different profile compared to compound 25, especially in terms of prolonged exposure within the posterior eye chamber (PEC). The area under the curve (AUC) ratio, reflecting Acrizanib's concentration in the PEC relative to its plasma levels, is significantly elevated, showing over 21000-fold higher exposure in the PEC compared to plasma by day 11. Additionally, Acrizanib demonstrates a substantially enhanced retina-to-plasma AUC exposure ratio after 10 days of administration (598× for Acrizanib versus 0.8× for compound 25)[1], distinctively unlike compound 25.
Synonyms	LHA510

Chemical Properties

Molecular Weight	445.4
Formula	C₂₀H₁₈F₃N₇O₂
Cas No.	1229453-99-9
Smiles	CNCc1cc(Oc2ccc3n(ccc3c2)C(=O)Nc2cc(n(C)n2)C(F)(F)F)ncn1
Relative Density.	1.47 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 37.8 mg/mL (84.87 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.49 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.2452 mL	11.2259 mL	22.4517 mL	112.2586 mL
5 mM	0.4490 mL	2.2452 mL	4.4903 mL	22.4517 mL
10 mM	0.2245 mL	1.1226 mL	2.2452 mL	11.2259 mL
20 mM	0.1123 mL	0.5613 mL	1.1226 mL	5.6129 mL
50 mM	0.0449 mL	0.2245 mL	0.4490 mL	2.2452 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc